About
Profile
We create breakthrough products – in diagnostics, medical devices, nutrition and branded generic pharmaceuticals – that help you, your family and your community lead healthier lives, full of unlimited possibilities. Today, 103,000 of us are working to
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
ABT
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Abbott posts 12% revenue drop amid baby formula disruption, waning COVID impact
- Abbott Laboratories Non-GAAP EPS of $1.03 beats by $0.10, revenue of $10.1B beats by $410M
- Abbott Q4 results in focus as DOJ probe on baby formula plant looms
- Abbott under DOJ criminal probe over behavior at Michigan baby formula plant - WSJ
- Catalyst watch: Tesla reverberations, Intel earnings, Rocket Lab launch and Macau stocks on holiday
- Abbott receives FDA approval for transcatheter aortic valve implantation system
- COVID-19 public health emergency extended by HHS, possibly for final time
- WHO sets Jan. 27 meeting to decide on COVID emergency
- CES 2023: What's happening at the Consumer Electronics Show?
- Wynn Resorts and Merck among Wells Fargo's conviction calls for Q1
- Diabetes rates in children set to skyrocket by 2060 - study
- Imported baby formula to face US tariffs again in 2023 - WSJ
- Goldman Sachs highlights key healthcare themes for 2023
- Abbott wins FDA approval of Eterna spinal cord stimulation system
- White House restarts program to ship free at-home COVID tests
- WHO chief hopeful COVID emergency will end next year
- Abbott Laboratories raises quarterly dividend by 8.5% to $0.51/share
- EU wants to delay medical device law amid supply challenges - Reuters
- Reckitt thinks U.S. baby formula shortage will persist until spring – Reuters
- World Health Organization renames monkeypox as mpox